Literature DB >> 223802

Grey scale ultrasound appearances in hepatocellular carcinoma.

J E Boultbee.   

Abstract

Thirty patients with histologically proven hepatocellular carcinoma were examined ultrasonically. All except two of these cases were reported ultrasonically as having a solid mass. Forty-three per cent of these lesions appeared multiple and 90% had irregular walls or boundaries. Stretching or distortion of the inferior margin of the liver is considered significant and 53% of cases demonstrated this feature. Just over two-thirds (67%) of the lesions were echogenic and under one-third (27%) were mixed lesions with echogenic and transonic areas. These transonic areas are considered to be due to the necrosis within the tumour. Most patients presented late and died within three months. Ninety per cent had clinical hepatomegaly or an epigastric mass. So far the main benefits of ultrasonography have been the recognition or exclusion of treatable disease such as liver abscess, cysts and congestive conditions of the liver, which may also present with unexplained hepatomegaly or epigastric masses. The possibility of a recognisable echo pattern for hepatocellular carcinoma emerged from this study. By conducting selective ultrasonic surveys in endemic areas and by employing the ultrasonic criteria described early diagnosis may be possible. Aspects of management and research may be assisted.

Entities:  

Mesh:

Year:  1979        PMID: 223802     DOI: 10.1016/s0009-9260(79)80193-2

Source DB:  PubMed          Journal:  Clin Radiol        ISSN: 0009-9260            Impact factor:   2.350


  2 in total

1.  Hepatocellular carcinoma masquerading as malignant teratoma.

Authors:  B Gorman; P Bryne; O Khan
Journal:  J R Soc Med       Date:  1985-11       Impact factor: 5.344

2.  ITGA7, CD133, ALDH1 are inter-correlated, and linked with poor differentiation, lymph node metastasis as well as worse survival in surgical cervical cancer.

Authors:  Na Yuan; Lei Wang; Qiang Xi; Niandong Zou; Xianyu Zhang; Xiurong Lu; Zhilin Zhang
Journal:  J Obstet Gynaecol Res       Date:  2022-02-22       Impact factor: 1.697

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.